{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:58:11Z","timestamp":1790546291754,"version":"4.1.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.heliyon.2024.e36922","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T15:06:43Z","timestamp":1724512003000},"page":"e36922","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Facial trauma with life-threatening bleeding treated by andexanet alfa administration: A case report"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-4587-9334","authenticated-orcid":false,"given":"Yasunori","family":"Shirakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4677-8881","authenticated-orcid":false,"given":"Naoto","family":"Jingami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Minami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Shinozuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Yunoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Ohtsuru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e36922_bib1","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/j.wneu.2019.04.108","article-title":"Japan Neurotrauma Data Bank Committee, Risk of deterioration of geriatric traumatic brain injury in patients treated with antithrombotic drugs","volume":"127","author":"Suehiro","year":"2019","journal-title":"World Neurosurg"},{"key":"10.1016\/j.heliyon.2024.e36922_bib2","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s40265-018-0940-4","article-title":"Andexanet alfa: first global approval","volume":"78","author":"Heo","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.heliyon.2024.e36922_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1254\/fpj.22107","article-title":"[Andexanet alfa (ONDEXXYA\u00ae for Intravenous Injection 200 mg), a reversal agent for direct factor Xa inhibitors: pharmacological characteristics and clinical evidence]","volume":"158","author":"Yajima","year":"2023","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"10.1016\/j.heliyon.2024.e36922_bib4","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"ANNEXA-4 investigators, final study report of andexanet alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.heliyon.2024.e36922_bib5","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"ANNEXA-4 investigators, full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e36922_bib6","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"ANNEXA-I investigators, andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e36922_bib7","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"ACC expert consensus decision Pathway on management of bleeding in patients on oral anticoagulants: a report of the American college of cardiology solution set oversight committee","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.heliyon.2024.e36922_bib8","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"External reviewers, 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.heliyon.2024.e36922_bib9","first-page":"1233","article-title":"Reversal agents for oral anticoagulant-associated major or life-threatening bleeding, Intern. Emerg","volume":"14","author":"Moia","year":"2019","journal-title":"Med."},{"key":"10.1016\/j.heliyon.2024.e36922_bib10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/23969873231220235","article-title":"Acute care bundles should be used for patients with intracerebral haemorrhage: an expert consensus statement","volume":"9","author":"Parry-Jones","year":"2024","journal-title":"Eur Stroke J"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024129532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024129532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:26:28Z","timestamp":1790544388000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024129532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":10,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2405844024129532"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36922","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Facial trauma with life-threatening bleeding treated by andexanet alfa administration: A case report","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36922","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e36922"}}